GB/T 39381.1-2020Cardiovascular implants - Vascular device-drug combination products - Part 1: General requirements (English PDF)
This is a limited preview
Buy now to download the full PDF
Need quotation for your management?
Get a formal quotation for GB/T 39381.1-2020 in 30 minutes.
Issued by
SAMR; SAC
Level / Type
National · Recommended
Issue date
November 19, 2020
Implementation date
December 1, 2021
Scope
GB/T 39381.1-2020 (Cardiovascular implants - Vascular device-drug combination products - Part 1: General requirements) is available as an English-translated PDF.
GB/T 39381.1-2020 is the Chinese standard "Cardiovascular implants - Vascular device-drug combination products - Part 1: General requirements".
Its scope clause reads: This part of GB/T 39381 specifies the requirements for the intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information provided by the manufacturer, etc. of the vascular device-drug combination products (VDDCPs).
NOTE 1: Due to variations in the design of combination products covered by this Part and due to the relatively recent development of some of these combination products, acceptable standardized in vitro test results and clinical study results are not always available.
As further scientific development and clinical data accumulation, appropriate revision of this Part might be necessary.
Delivery systems or parts of the delivery system are included in the scope of this Part, if they comprise an integral component of the vascular device and if they are drug- covered (e.g.: drug-covered balloon catheters and drug-covered guidewires).
This Part is also applicable to the non-permanent implantable VDDCPs.
Devices whose PMOA is to provide a conduit for delivery of a drug, are excluded from the scope of this Part (e.g.: infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g.: antimicrobial coated central venous catheter).
Procedures and devices used prior to and following the introduction of the VDDCP (e.g.: balloon angioplasty devices) are excluded from the scope of this Part if they do not affect the drug-related aspects of the device.
This Part includes the requirements for the absorbable components (such as coating) related to the device drug in the VDDCPs. NOTE 2: See also ISO/TS 17137. This Part does not address issues associated with viable or non-viable biological materials such as tissues, cells, or proteins.
This Part does not address issues associated with active surgical implants (i.e.: implants that require power not generated by the human body or gravity).
Found what you need?
Document preview — GB/T 39381.1-2020
National Standard of the People's Republic of China
Issued by: SAMR; SAC
Contents
- Foreword3
- Introduction5
- 1 Scope6
- 2 Normative References7
- 3 Terms and Definitions8
- 4 Intended Performance12
- 5 Design Attributes13
- 6 Materials15
- 7 Design Evaluation15
- 8 Manufacturing32
- 9 Sterilization35
- 10 Packaging36
- 11 Information Supplied by the Manufacturer36
- Bibliography46
1 Scope
This part of GB/T 39381 specifies the requirements for the intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information provided by the manufacturer, etc. of the vascular device-drug combination products (VDDCPs).
NOTE 1: Due to variations in the design of combination products covered by this Part and due to the relatively recent development of some of these combination products, acceptable standardized in vitro test results and clinical study results are not always available. As further scientific development and clinical data accumulation, appropriate revision of this Part might be necessary.
Delivery systems or parts of the delivery system are included in the scope of this Part, if they comprise an integral component of the vascular device and if they are drug- covered (e.g.: drug-covered balloon catheters and drug-covered guidewires). This Part is also applicable to the non-permanent implantable VDDCPs.
Devices whose PMOA is to provide a conduit for delivery of a drug, are excluded from the scope of this Part (e.g.: infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g.: antimicrobial coated central venous catheter).
Procedures and devices used prior to and following the introduction of the VDDCP (e.g.: balloon angioplasty devices) are excluded from the scope of this Part if they do not affect the drug-related aspects of the device.
This Part includes the requirements for the absorbable components (such as coating) related to the device drug in the VDDCPs.
NOTE 2: See also ISO/TS 17137.
This Part does not address issues associated with viable or non-viable biological materials such as tissues, cells, or proteins.
This Part does not address issues associated with active surgical implants (i.e.:
implants that require power not generated by the human body or gravity).
2 Normative References
The following documents are essential to the application of this document. For the dated documents, only the versions with the dates indicated are applicable to this document; for the undated documents, only the latest version (including all the amendments) is applicable to this document.
GB/T 16886.1 Biological Evaluation of Medical Devices - Part 1: Evaluation and
Testing within a Risk Management Process (GB/T 16886.1-2011, ISO 10993-
1:2009, IDT)
GB/T 16886.2 Biological Evaluation of Medical Devices - Part 2: Animal Welfare
Requirements (GB/T 16886.2-2011, ISO 10993-2:2006, IDT)
GB/T 16886.7 Biological Evaluation of Medical Devices - Part 7: Ethylene Oxide
Sterilization Residuals (GB/T 16886.7-2015, ISO 10993-7:2008, IDT)
GB/T 19633.1 Packaging for Terminally Sterilized Medical Devices - Part 1:
Requirements for Materials, Sterile Barrier Systems and Packaging Systems (GB/T 19633.1-2015, ISO 11607-1:2006, IDT)
GB/T 19974 Sterilization of Health Care Products - General Requirement for
Characterization of a Sterilization Agent and the Development, Validation and
Routine Control of a Sterilization Process for Medical Devices (GB/T 19974-2018,
ISO 14937:2009, IDT)
YY 0285.4 Intravascular Catheters - Sterile and Single-Use Catheters - Part 4:
Balloon Dilatation Catheters (YY 0285.4-2017, ISO 10555-4:2013, MOD)
YY/T 0316-2016 Medical Devices - Application of Risk Management to Medical
Devices (ISO 14971:2007 corrected version, IDT)
YY 0450.1 Accessory Devices for Sterile Single-Use Intravascular Catheters -
Part 1: Introducers (YY 0450.1-2003, ISO 11070:1998, IDT)
YY/T 0466.1 Medical Devices - Symbols to be Used with Medical Device Labels,
Labelling and Information to be Supplied - Part 1: General Requirements (YY/T 0466.1-2016, ISO 15223-1:2012, IDT)
YY/T 0640-2016 Non-Active Surgical Implants - General Requirements (ISO 14630:2012, IDT)
YY/T 0663.2 Cardiovascular Implants Endovascular Devices - Part 2: Vascular
Stems (YY/T 0663.2-2016, ISO 25539-2:2012, MOD)
YY/T 1680 | YY/T 1571 | GB 24436 | GB/Z 44426.7 | […]
......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — all pages — is available in the English PDF.
Referenced standards
Normative references
- GB/T 16886.1Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
- GB/T 16886.1-2011Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
- GB/T 16886.2Biological evaluation of medical devices - Part 2: Animal welfare requirements
- GB/T 16886.2-2011Biological evaluation of medical devices - Part 2: Animal welfare requirements
- GB/T 16886.7Biological evaluation of medical devices—Part 7: Ethylene oxide sterilization residuals
- GB/T 16886.7-2015Biological evaluation of medical devices—Part 7: Ethylene oxide sterilization residuals
ISO 10993 · ISO 11607 · ISO 14937 · ISO 10555 · ISO 14971 · ISO 11070 · ISO 15223 · ISO 25539
How to Download GB/T 39381.1-2020
- 1
Add to cart
Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.
- 2
Checkout
Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).
- 3
Instant delivery (0–9 sec)
Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.
- 4
Invoice included
A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.
Related Standards
GB/T 16886.1-2022 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
GB/T 16886.2-2011 — Biological evaluation of medical devices -- Part 2: Animal welfare requirements
GB/T 16886.2-2026 — Biological evaluation of medical devices - Part 2: Animal welfare requirements
Secure payment via Stripe
Payments accepted
GB/T 39381.1-2020
$420.00